In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Light Sciences LLC

Division of Light Sciences Oncology Inc.
www.lightsci.com

Latest From Light Sciences LLC

The Medical Device Industry's Robust Times, Part 2: The New Device Model

The general renaissance in the medical device start-up world that began several years ago came about becuase of a very specific business model--small companies would develop innovative new technologies without worrying about building their businesses, and large companiess would acquire their products to fill their pipelines. In the current climate, however, a number of factors are pushing back against this model.
Medical Device

Device Financings: Recent Growth, Future Opportunities

A Reprint--see the article of the same name in In Vivo, May 2008.

Device Financings: Recent Growth, Future Opportunities

In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.
Medical Device

Visible Progress in Devices for Age-Related Macular Degeneration

A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
Medical Device Combination Products
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Ophthalmic
  • Alias(es)
  • Light Sciences Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Light Sciences Oncology Inc.
  • Senior Management
  • Albert Luderer, PhD, Pres. & CEO
    Karen Wetzel, CFO & Dir., Fin. & Admin.
    James Chen, MD, CSO & CTO
    Nick Yeo, VP, Strategic Bus. Dev.
  • Contact Info
  • Light Sciences LLC
    Phone: (425) 369-2800
    34931 SE Douglas St.
    Ste. 200
    Snoqualmie, WA 98065
    USA
UsernamePublicRestriction

Register